Latest / HumanifAI HealthTech / Can AI Solve Wound Care’s Silent Epidemic? w/ Dr. Thomas Serena, Founder & CEO, SerenaGroup
Transcript
- 0:00A diabetic foot ulcer can go from unnoticed to amputation in a matter of weeks or even days.
- 0:07And for patients who undergo a major amputation, more than 50% may die within five years.
- 0:13Those are worse odds than most cancers, and almost nobody's talking about it.
- 0:19Yet the clinicians fighting it are also busy fighting paperwork, burnout, and a reimbursement system that feels like it's turning against them, even if it's not.
- 0:31Today's guest is using AI to get clinicians out from behind their screens and back to the patients who need them, while speeding up the research that could save limbs and lives.
- 0:48Welcome back to Humanify Health Tech, where we explore how AI is rewriting the rules of healthcare and putting people back at the center where they belong.
- 0:57I'm your host, Brian Chi from Net Health Today we're joined by an absolute titan of healthcare, Dr. Thomas Serena, founder and CEO of Serena Group, which connects 30 advanced wound centers with 283 clinical research sites worldwide.
- 1:13He's a world-renowned surgeon who's led well over 100 clinical trials and published hundreds of peer-reviewed papers.
- 1:23Today, he's here to explain how AI can protect a clinic's margins, rescue nurses from burnout, and get life-saving cures to patients sooner.
- 1:35Tom, welcome to the show.
- 1:37Thanks, Brian.
- 1:38I'm very happy to be here.
- 1:39And do you-- Are you wearing your Superman cape and outfit underneath that?
- 1:43Because that's a whole lot of stuff that you're gonna do there.
- 1:46No, actually, I put on the, uh, you know, I put on the, the shirt for the recording.
- 1:51I had my Metallica, uh, shirt on prior to that.
- 1:54Uh, you know, we got to see them at the Sphere at the, um, uh, you guys were at SAWC- Yep the, the annual meeting, so we got to see them at the Sphere- Yeah … while we were attending the annual wound care meeting.
- 2:05Yeah, and I saw, I saw that and, um, that must have been great.
- 2:08How was the show?
- 2:09How was the conference?
- 2:10Fabulous.
- 2:10We went two nights.
- 2:11Uh- Yeah … we went Thursday and Saturday- Yeah … uh, at the SAWC.
- 2:14Uh, I've tried to talk the A- SAWC folks into coordinating all of their meetings with, you know, uh, Sphere events in the future when we're in Vegas.
- 2:24Absolutely, right?
- 2:25I mean- … come on, right?
- 2:26That's a, that's a, that's a no-brainer.
- 2:27That's the way it should be.
- 2:28Yeah.
- 2:28Yeah.
- 2:28Hey, I wanna thank you, by the way, for f- just, you know, I just wanna thank you for writing that real clear policy piece because I think, you know, for, for me, um, it brought a lot of common sense to, uh, an area that feels a little bit chaotic right now.
- 2:44And so, like, it almost felt like as though you were the, you were the guide, the, the, the guru in the room, I guess I would say, kind of providing some perspective on skin subs and what's, what's currently happening in the space.
- 2:59And, and- It's- … I think that's mu- much needed, right?
- 3:02Well, yeah.
- 3:03Thank you.
- 3:03Maybe the-- I, I haven't got a lot of feedback on that.
- 3:05Thought I was gonna hear a lot about that, but I didn't.
- 3:07I haven't yet.
- 3:08Maybe I'm a-- Maybe there's a dartboard at Medicare with my picture on it.
- 3:11Probably is.
- 3:12Uh, you know, uh, so I-- But I don't disagree with what Medicare did, right?
- 3:16I mean, there was a lot of abuse in the skin sub space.
- 3:19Uh, and, but it wasn't, it wasn't us.
- 3:22It wasn't the people that l- live and breathe wound care and have done so for decades.
- 3:27And it-- That wasn't the group.
- 3:29It wasn't, it wasn't Net Health pushing it.
- 3:31It wasn't, you know, Serena Group.
- 3:33It wa- it was people that came into the space to make a lot of cash right away, and then they disappeared, and they're gone.
- 3:39And now, uh, and now there's this pushback from the government.
- 3:43And again, it's really hard to criticize them for it simply because there was waste, fraud, and abuse.
- 3:49Uh, but I'm afraid that the abusers now have left- And we're left now being, you know, uh, uh, with, with Medicare, you know, uh, trying desperately to take away, uh, you know, a lo- our livelihood.
- 4:02Uh, and, uh, and I don't mean to sound dramatic, but it's true.
- 4:05Uh, not only with, um, uh, with all the clawbacks that are happening, uh, with, uh, the skin subs, uh, but now most recently with the non-coverage LCD for MolecuLight Mimosa and, um, and Kent.
- 4:18I, I don't know what we're gonna do without diagnostics.
- 4:20That's, you know, uh, that's, uh, really a very, very difficult, um, uh, that's really a very, very difficult, uh, piece, um, uh, to, to get, get over.
- 4:30I, it feels like to me that you're… I think, I think on a, on a podcast not too long ago, so- I think the host called you a Renaissance man, which I thought was pretty- which I thought was pretty cool.
- 4:40But what you were saying right there kind of like underlines the, the point of what she was saying too, but in a different way, which is essentially you, you are looking at the, what's currently happening in wound care from a really broad perspective, right?
- 4:54From, from the clinic floor right into Washington, and you kinda see how, see how this is playing out.
- 5:01You know, what, you know, where are we going?
- 5:05You know?
- 5:05And that's a large question, but, you know, this is a silent epidemic.
- 5:10Everybody calls it that.
- 5:11I almost feel like as though it's le- less silent than it is hidden.
- 5:14And, and as you're looking at the changes that are un- unfolding, um, as the Renaissance man, what's your, what's your view?
- 5:23Well, thank you.
- 5:24Uh, the-- So I'm, I'm still very bullish on wound care.
- 5:27Wound-- These patients with wounds aren't going anywhere.
- 5:29And, you know, the great news is that we keep people alive a lot, a lot longer than we used to.
- 5:35I mean, we've got biologics and all kinds of fabulous treatments.
- 5:39Uh, and, and, you know, the infectious disease has become less of a problem, and heart disease, and we're getting better at it.
- 5:44But one thing we're not getting better at is, is keeping patients' skin intact.
- 5:48And the longer they live and the more, uh, the more, uh, sort of poisons we give them in order to save their lives, the more likely they are to have skin breakdown.
- 5:58So the problem is not going to go away.
- 6:00No matter what Medicare does, problem's not going away.
- 6:03And, and what will happen is the pendulum will swing back because these patients, uh, will end up in the ER, they'll end up in the hospital.
- 6:10They'll, you know, there'll, there'll be a pushback, uh, from the patients.
- 6:13You know, if you're, if you got a pr- God forbid you're a, uh, you live in a rural community and you have a pressure ulcer, uh, you know, that, uh, these recent changes are gonna put you in, in, in harm's way.
- 6:25And, uh, you know, the, you know, over 15% of all prescriptions for antibiotics are written, uh, uh, by wound care pe- wound care people in some fashion, whether it's, you know, wound in the ER or wound in the wound clinic.
- 6:39That's an enormous amount of antibiotics.
- 6:41And yet take away diagnostics that de- substantially decrease the number of antibiotics that are used.
- 6:47It makes no sense to me.
- 6:48We're going to drive antimicrobial resistance.
- 6:52We'll have more problems with, you know, C. diff and other issues like that.
- 6:56And then we'll have more issues, uh, with antibiotics that don't work, and we have to drive, um, uh, that.
- 7:02In, in the long run, you can't ignore wounds because they will come back to bite you later on.
- 7:07I mean, uh, a, you know, decreasing reimbursement and, and, and, and, and decreasing the ability to care for these patients is, is going to bite Medicare again, without a doubt, because they're not going anywhere, and everything they've done is going to, is going to increase later costs.
- 7:25Uh, it's kicking the can.
- 7:26What you're saying there is like the, the wound in wound care is that you're having increased need, right?
- 7:33More diabetic patient needs and g- you know, an explosion, an explosion, that epidemic com- com- part of that.
- 7:41You've got these sweeping policy changes that are, um, that are, that are ha- that are happening in real time almost, or at least it feels like it.
- 7:49And then, uh, and in addition to that, you've got this clinician burnout.
- 7:53And, and like what you're saying there, what I read and from what you're saying is that the, the solution currently is more wounds are gonna pop up in more places, like ERs and things like that, yet that's not the solution that's needed to heal wound care itself.
- 8:09You mentioned diagnostic, you know, d- d- uh, advanced diagnostic capabilities.
- 8:14That's part of it, right?
- 8:17I think of this as a whiplash application of technology ultimately.
- 8:22Sure.
- 8:22Because some sides, payer to provider, have technology that they're using, others don't.
- 8:29And as the result of it is just chaos and not care.
- 8:34Is that right?
- 8:35Am I-- Do I read that right?
- 8:36No, I think you, you, you're good.
- 8:37I think one of the, you know, I, I testified in, uh, from Palmetto, uh, the MAC this morning, and basically what I told them was, uh, the, the use of antimicrobials and antibiotics in the wound care space at the moment, based on really good data, is completely haphazard and random.
- 8:55You might as well, when a patient comes into the wound clinic, you might as well flip a coin.
- 8:58Should I give them antibiotics or not?
- 8:59Flip a coin.
- 9:00That's the state of the art.
- 9:02We, we, over the last, you know, since 2018, we were able to change that with these new diagnostics and really, and really hone in on what's going on in the wound.
- 9:11And then, uh, just as we're about to get a Category 1 code for the fluorescence imaging, which really solidifies it as part of practice, uh, they issue non-coverage.
- 9:21I, you, you, you got me on this one.
- 9:23Don't understand it at all, because that diagnostic's gonna save money, uh, in the, uh, in the short term and in the long term, and I don't understand why, why you would do it.
- 9:34I, I, I basically, I said to them,"I would do the exact opposite.
- 9:38I would mandate it." You know?
- 9:40And if you don't wanna pay $118, pay less, but don't pay zero.
- 9:45You know, don't, don't say it doesn't work.
- 9:46Uh, that's just, that's just silly.
- 9:48I mean, we need to have this device in our hands.
- 9:51Uh, and, uh, a- and among the other ones, I mean, there, there, you know, there's… We need diagnostics in the wound care space without a doubt.
- 9:58There's just… Uh, you know, we, y- it's like taking the EKG away from a cardi- a, a cardiologist along with the echo.
- 10:04Say, "Oh, cardiology, you can practice anymore. No EKG, no echo. We'll just cath everybody." Yeah, and it's almost like a, it's like, it's like, it's almost like a, like a sort of blanket approach when more precision is necessary, um, a- and the technology is there to provide that, that level of precision.
- 10:23It's like every… What you're saying reminds me of the SkinSup thing, right?
- 10:26Because, because, because w- what, what CMS did, I mean, what you wrote in that, in that article was what CMS did wasn't wrong.
- 10:34It needed to change.
- 10:35But maybe the fact that there was just a blanket change of a, a, a 127 is not the change that was needed, that maybe more precise changes were needed in order to protect the ethical clinicians that were actually healing people.
- 10:51Yeah, I, you know, I'm a little disappointed that, uh, that, that we didn't have any-- we didn't get to give more input.
- 10:56I mean, I, I-- it's not, it's a problem we could've solved.
- 10:59I mean, you know, I, for example, I would've mandated fluorescence imaging prior to the use of the skin subs.
- 11:04That would've decreased your use and increased out better, uh, outcomes and decreased costs.
- 11:09A simple… And I suggested that to the MAC.
- 11:11I mean, I suggested it on the open meetings that this is what I would do.
- 11:15Uh, and you know, uh, who am I?
- 11:16I've just been doing wound care for 30 years and done almost, you know, done, you know, more than half of the research in this space has been done by our group.
- 11:23So, uh, anyway, I don't wanna-- I won't, I will never understand, uh, uh, h-how this whole process works.
- 11:29But, you know, and then leveraging, uh, leveraging AI.
- 11:32I mean, we just, we, the, we were talking about that.
- 11:34We, we are now, uh, using AI as, uh, everybody is.
- 11:40Uh, but, but why, what an amazing, what an amazing tool both in documentation, uh, and decreasing burnout because you're not spending all your time in front of the computer screen clicking.
- 11:49Uh, and, uh, and then, you know, on the research side, the data analytic abilities are just un- you know, unbelievable.
- 11:56Um, so, uh, you know, uh, I think there's, there's a future.
- 12:01Um, and if, if we survive long enough, uh, we'll be able to take advantage of it.
- 12:05I mean, I mean, there's like a, there's like a… We're in a transitionary period.
- 12:08Is that, is it true that, like, we're in a transitionary period?
- 12:11Because, like, let's, let's, let's, let's talk about, um, in- um, inconsistent application of technology like AI, right?
- 12:20Exactly.
- 12:20Um, WISR is, uh- Mm-hmm … is, is something, a pilot program that, um, the CMS is rolling out.
- 12:27You said in that ar- in the same article that I talked about with that, that it could probably could, could need some adjustment there, right?
- 12:33At- Sure.
- 12:34That's, that's an example of advanced technology that maybe isn't completely consistent with what it could do.
- 12:42On the other side of that, the-- on the provider side, a lot of providers aren't using technology like AI in order to submit, to submit their claims.
- 12:51As CMS grows more advanced in terms of, um, in terms of auditing and examining claims, providers who are not, who are still using paper rulers, for example, are, are probably going to see a lot more risk.
- 13:06Is that right?
- 13:08Yeah.
- 13:08I mean, one of the things that we-- that's gotta happen, uh, in wound care is, i-is the adoption of technology.
- 13:14Like, I mean, just look at all the measuring tools that are out there now, you know, that to, to measure surface area, and hopefully soon measure volume, and there's some that will be doing that, uh, in the future as well.
- 13:25I mean, you know, uh, uh, the, the idea that you're still using a ruler length times width is, is really, um, wow.
- 13:33I mean, that's like Florence Nightingale type wound care.
- 13:36Um, and, uh, and they-- uh, we haven't progressed a lot further f- than that.
- 13:40I, I don't know how you decide whether you're gonna use advanced therapy or not if you are, um, uh, if you're, um, if you're still using a wid- width length times width.
- 13:50You need to have surface area, you need to have volume.
- 13:52We need to become sophisticated.
- 13:54Uh, also aside that, just to be adopted by the rest of the wound, uh, medical community, we, we need, we need to advance along with our, our, our technology.
- 14:02You know, an interesting thing, I don't wanna go too sideways, but the NIH has a great working group on biomarkers.
- 14:07Um, and they're collecting biopsies, and it's really a great in- initiative.
- 14:10I was a part of the initial review of it, uh, and I, I was just really excited about it until we got to this, until we got to this recent decline of, um, uh, payment for established biomarkers.
- 14:21I mean, I turn back and look at the NIH, why are you spending the money?
- 14:25I- if Medicare's not gonna pay for what you discover, why sp- why do it?
- 14:29You should cancel that program and, a- and invest in AI or something instead of biomarkers.
- 14:35Uh, because, um, you know, you may discover a biomarker in this NIH study, but if you do, you won't be able to do anything with it.
- 14:42But we're sort of past the point there where, um, it's an option not to do something like that, right?
- 14:48I mean, it, it, it… Given, given where, where wound care sits as an epidemic and, and the reality that the technology is available to become even more precise and to actually pay clinicians m- in a, in a more stable, consistent way, it feels like as though that that's not an option, that, uh, the adoption of technology across all aspects of wound care has to take place both in terms of the payer, CMS, and the provider, these large health systems.
- 15:22Is that right?
- 15:23Yeah, that's right.
- 15:24I was being a little hyperbolic there, but, you know, just, uh, because it's, it's a little bit, it's just a little bit frustrating.
- 15:29Um, you know, uh, you know, we adopted fluorescence imaging and near-infrared spectroscopy before it was paid for.
- 15:36So right now we're covering that cost, and I'm not gonna stop using it.
- 15:40Don't tell Medicare.
- 15:41We gotta hope they're not watching.
- 15:42Um, I'm not gonna stop using 'cause I need it.
- 15:44My patients need it, you know?
- 15:46And, you know, I can d- you know, we show that adding fluorescence imaging across a broad spectrum of, of wound care centers decreased antibiotic use by almost 50%.
- 15:56Show me an antibiotic stewardship program that's better than that.
- 15:58There- not, not any one has been published.
- 16:01So 50% reduction in antibiotics, and think about how many cases of C. diff alone that decreases.
- 16:06Uh, and, and the cost that, uh, the cost and the, and the patient cost of, um, uh, of that.
- 16:13Uh, you know, no.
- 16:13So obviously I'm not gonna stop using it, but it'd be nice if you actually, you know, if I didn't have to take loans out to continue practicing.
- 16:20So is that like… So, so the common, the common way of thinking there is, "Yeah, yeah, yeah, yeah, CMS is gonna catch up," right?
- 16:26I mean, is this- Mm-hmm.
- 16:27And, and, and, and stop me if I, if I misspeak here, but the sort of, the sort of pervasive of, of attitude probably across healthcare is,"Yeah, yeah, CMS is gonna catch up.
- 16:39I'm gonna continue to use this technology, like what you're talking about, because it's, it's saving lives, it's healing people, it's effective.
- 16:48And I know that eventually there's gonna be a rule that will correct things and, and this will all come good." Um, is that, is that true, first of all?
- 16:58And if that's true, is that changing now that things are so much faster, that technology is making things so much more, um, light speed in terms of the development of healing technologies and payment technologies?
- 17:13Yeah, you know, we're gonna take care of patients.
- 17:14That's our primary mission.
- 17:16And so, you know, it-- we've adopted the technology, we paid for it, uh, and we're gonna continue using it.
- 17:21And, uh, hopefully Medicare will catch up.
- 17:23I think they will.
- 17:24Uh, I think right now, um, you know, uh, I think, uh, the MACs, the Medicare Administrative Contract, sort of a bad taste in their mouth when it comes to wound care fi- folks because they see us as, uh, they, they see those very few patients that took advantage, and now they, they've painted the, with a broad brush to everybody in the space.
- 17:43And so I, I think honestly, uh, to be very frank, I think it'll all s- it'll all swing back and it'll all work its way out.
- 17:48It, it, it, it almost alway- it, it almost always does.
- 17:51It's just frustrating for providers in, in the short term.
- 17:55You know, if you have a wound clinic and you really think you're doing a great job, but you can't afford the technology or your hospital won't buy it because now it has no reimbursement, you're not gonna buy it.
- 18:03Um, you know, we took a different tack and we said, "Look, we're gonna use some of our profit to invest in technology because it's good for patient care and patient outcomes." And honestly, uh, uh, and on the research side, you just can't… You know, you would never do a research clinical trial without having technology to measure the wound accurately.
- 18:22I just wonder if health systems can afford to do that.
- 18:25Like, you know, and, and if that's something that's gonna continue to be the case where, um, they lead and CMS follows because they're, they're, uh, looking, looking to heal, and that's, um, you know, it's interesting.
- 18:39Some will and some won't.
- 18:41You know, some, some simply can't afford it.
- 18:42If you, you know, if you're operating at an inner-city wound care center, you can't afford to add all this technology on, on board.
- 18:47But, you know, uh, then again, if you're, uh, if you're going to be one of the wound care centers, uh, of excellence that survives, you're gonna have the technology because y- y- you know, your reputation's built on actually healing people.
- 19:00Uh, and, uh, and so, and without this technology, your, the healing rates will be much lower.
- 19:06So one of the things that, you know, like there's a thing about AI, right?
- 19:10That AI solves everything.
- 19:11When- … in, in the healthcare space, AI, AI is gonna solve everything.
- 19:15It's beautiful.
- 19:16It's this wonderful thing.
- 19:17All of a sudden, all of my unstructured data is structured.
- 19:21I can find all this great thing, all, all, all these g- all these great findings.
- 19:25But here's my question to you about that.
- 19:27First of all, is that true, right?
- 19:28Right.
- 19:29Secondly is has AI or automation actually introduced opportunities to gameplay and provide unscrupulous, unscrupulous operators with fraudulent opportunities?
- 19:45Like I'm going back to skin subs or d- that's just an example, right?
- 19:48Yeah.
- 19:48But when you think about automated billing, things like that, does that open the door, Pandora's box, to problems with reimbursement?
- 19:58And is that what CMS is reacting to?
- 20:00Well, you know, that's a really great question because, you know, uh, you know, we were just at a, um, hospital conference, and we have our own AI department, and the buzzword now is governance, right?
- 20:10Uh, you know, how do we, you know, how do you, how do you prevent, uh, e- accidentally from doing that?
- 20:16But no, if you're a really sharp operator, uh, you could, y- I mean, AI can make up patients, uh, you know, it, it much better than the old fraudsters could, you know?
- 20:25Um, and so yeah, no, the, the potential for AI to, uh, uh, for fraud in AI is, is really, uh, very, as you know, very, very high.
- 20:34And, um, it's something we, that, uh, that has been, that is talked about at all the different conferences.
- 20:39But, you know, how do we prevent that?
- 20:40I mean, for us, you know, as we're looking at, say, research data with AI, uh, geez, how do we, you know, how do we, um, how do we make sure it's right?
- 20:49I mean, how do we double-check it to make sure that it, you know, doesn't hallucinate or doesn't, you know, put, it doesn't misunderstand the prompts, which is probably more common than hallucination.
- 20:58Uh, how do we make sure that we get it out of the, uh, out of, like, the medical record, uh, without, you know, with- in a de-identified fashion?
- 21:06Because that's one of our challenges too.
- 21:07Put it in the, um, uh, EMR, pull out the data, uh, but don't pull out any, uh, you know, PHI.
- 21:15Don't pull any, uh, protected health information on it.
- 21:17And, you know, we, we had to play around with that in s- in at least on the research side already, where it pulls out the wrong stuff.
- 21:23You're like, "Oh, damn," you know, "Now we gotta, we gotta start all over again." Uh, how much of a game changer on, on that score, how much of a game changer is ambient for, for wound care?
- 21:33You know, I mean, ambient's been around for probably 10 years more.
- 21:36Yeah.
- 21:37It's, it's common now pretty much, but, but, you know, we're not… W- we think about it at the bedside.
- 21:42Wow, that, that, that nurse, that clinician can, can actually look at somebody and not have to look down and type away.
- 21:49Yeah.
- 21:50But what's more interesting to me is how does that work from, from your perspective when you're gathering that data and using it for your clinical trials?
- 21:58Does that, uh, is that better?
- 22:00Is that, uh… Or, or are there problems?
- 22:03Well, there are problems.
- 22:04There we, I mean, there's always gonna be problems with everything, but I, I love it.
- 22:06I mean, we, you know, it saves us enormous amounts of time.
- 22:10You know, and monitoring and things like that.
- 22:11I mean, you can put a… AI can look to make sure all the… I mean, something simple that we used to have, a person used to go in and do, right?
- 22:18Are all the boxes checked?
- 22:20You know, uh, you know, oh, you know, and, uh, things of that nature or, you know, does, does, you know, look at all the blood pressures in the tr- clinical trial.
- 22:28Are they all reasonable?
- 22:30You know, does it say 80 over 70, which you see?
- 22:34You know, oh, that was a typo.
- 22:35Well, okay, the AI can pick that up right away, and it just makes your life a whole, um, it makes your life a whole lot easier.
- 22:41There's no doubt about it.
- 22:42And when you're going to analyze data, uh, when you notice trends, whether it's in the regular EMR or whether it's in the, you know, the clinical trial EDC, uh, you can say, "You know, it seems to me like all the wounds that are bigger than two square centimeters are, are having a problem in this trial." So AI can-- You can go into AI and just say, "How many wounds are there greater than two, and what's their percent error reduction for the last four weeks?" You know, we used to do that.
- 23:08We used to do that analysis.
- 23:10Yeah, a student went in there for three weeks.
- 23:13You know, now AI goes in for three minutes.
- 23:15Um, you know, so, uh, it's, it-- that has just, that has revolutionized, uh, uh, the research world, and it's beginning, as you just mentioned with Ambient and that, and, uh, it, it's beginning to filter down into the clinical tr- uh, into the regular clinic visits, which is great.
- 23:31And I, I… The feedback you get from clinicians, the nurses, the docs, is all positive, you know, because we're not spending as much time, you know, at, at, you know, on, in front of the computer.
- 23:41We actually talk to patients now.
- 23:42That's a novel idea.
- 23:44Is it, you know, when w- I know you, uh, you testify, um, all the time, right?
- 23:51In, in, in front of administrative law judges, um, in terms of audits with, with providers.
- 23:56Is, is the use of Ambient a defensive shield for providers?
- 24:01Is that, does that provide more rigor and, and, and maybe incrementally or, or not, more, more effective defense when, when they're in that situation?
- 24:14So, uh, y- there's two things that happen at the ALJ.
- 24:16One is the, the typically the UPIC, the first au- first row of auditer, auditors, i- is going after the documentation.
- 24:24So if you're using Ambien and you're doing your documentation, you have your, you have it set up right.
- 24:28Someone's really helped you get the thing set up right, uh, which we have, and we were actually helped by you guys.
- 24:34So it was, it was good.
- 24:35Um, and, uh, then your documentation is good.
- 24:39If, if we get to an ALJ and the documentation's good, at that point, it, it's basically just an argument about, about, you know, whether the products really do meet, uh, medical necessity criteria, you know.
- 24:51And, you know, uh, I'm not sure Medicare knew they had a program integrity manual.
- 24:56That's a joke.
- 24:57Uh, but, uh, because I never heard them quote it until recently, but, uh, the, there is a Medicare program integrity manual.
- 25:02It's, it's very detailed.
- 25:04Uh, but, uh, there is a section in chapter 3, you know, uh, uh, 3 point, what is it, 3.6.2.2.
- 25:11I got it memorized now'cause I did it so much.
- 25:13But it's, um, uh, uh, but basically what it says is that you need to have a clinical trial for a product in order for it to be considered, continued, um, considered medical, uh, medically reasonable.
- 25:24Uh, that is not experimental, not investigational, safe and effective.
- 25:27Uh, I, I'm not sure any of us realized, including me, to be fair, realized that that was in there.
- 25:32Uh, and, um, and now it's something that the MACs have, have found and said, "Look, uh, you know, for decades we've had this rule that in order to, for us to pay a lot of money for something like skin subs, you have to have a clinical trial." That's a r- look, that's reasonable.
- 25:50Now, what wasn't reasonable was the timeframe they gave us.
- 25:52Didn't given us, they didn't give us enough time to get all the trials done.
- 25:56Uh, but, uh, but requiring a trial for a product 100% reasonable.
- 26:01I don't have a problem with that at all.
- 26:03Uh, they should've given us three years or so to get, to get it, um, finished.
- 26:07Now, most of the companies that I think are really stellar companies, uh, when in April 2024, when the MAC said, "Look, you gotta have a trial for all your products if you wanna get paid based on this Medicare, Medicare Program Integrity Manual," they started doing trials.
- 26:21And you'll see-- what you're ha- seeing now is this flurry of publications between, well, actually between September, you know, last month, and December this year, there's gonna be 15, 20 publications of clinical trials started back in April of '24, and now, now completed with really good data.
- 26:38And I will tell you the-- we don't have any trials where the skin subs have not been effective and safe.
- 26:43So it turns out that we were right, they are safe and effective, and now we have data, uh, to, to demonstrate that.
- 26:50So I think, uh, you know, I-- that's a positive side of, you know, all these changes was that, you know, we gathered an enormous amount of data.
- 26:57We-- in 2025, we had 20,000 investigational site visits.
- 27:01Uh, that's-- if you'd have said to me, uh, y- y- Brian, if he'd have come by and said to me, "Can you do 20,000 visits in, in research in a year?" I'd say,"No way in hell." And yet it happened, and, uh, and we, you know, we didn't sleep much, but we did make it happen.
- 27:17Uh, and so now we're in a situation, I think it's, that's really good.
- 27:20We have a lot of data.
- 27:21Look for those publications are gonna be coming out one on, one after another.
- 27:25But it's not just the skin sub data You know, it really led to, uh, you know, a, a lot of, a lot of data on diabetic foot ulcers and venous leg ulcers, pressure ulcers that we just didn't have before, and we'll, we'll be able to incorporate that now into, into regular practice.
- 27:40As you know, you know, when you-- typically in medicine, right, things go from clinical trials into regular practice, and I think I s- I'm beginning to see that more and more with AI and with everything else.
- 27:51Things that we've been doing in, in trials for two or three years, we're now seeing in, in the clinics.
- 27:56And, uh, and you'll see the same thing with-- A- and that goes with technology.
- 28:00We- one of the trials, uh, uh, and I don't wanna use a name, but you can look it up, but, uh, uh, allowed us to, uh, use, uh, uh, Dexcoms, the w- that you wear.
- 28:09Sorry to use a trade name, but it, uh, the glucose, continuous glucose monitor.
- 28:13Uh, so, uh, um, uh, so during the trial, because, you know, hemoglobin A1Cs, uh, don't correlate wound healing.
- 28:19We know that.
- 28:20And, and we did a-- A- and so that, the, the sponsor of that trial, uh, graciously allowed us to do that during the trial, and it's kind of a pain in the butt for them.
- 28:29They had to pay some extra money, took a little extra time, uh, but they were dedicated to finding the answers out.
- 28:34And we haven't published it yet.
- 28:35That's still in, in process.
- 28:36But that's one of the things we'll find out is, a- a- and I'm sure it's gonna correlate well, basically how, what your glucose control is compared to how well you, how well you heal.
- 28:47And, uh, so one of the beauties of, of this… I mean, the other thing that's really interesting as well is, you know, is, um, the FDA's published guidance on registries, which is really tough.
- 28:56We used to go into the EDCs and just pull out data, and that's our registry.
- 29:00That's great, uh, but that's not what they want.
- 29:04Uh, they actually want the data collect, uh, collected prospectively if you're gonna make marketing claims, and I think that's something that we've embarked on as well that's really pretty exciting.
- 29:14So what, what I'm learning here is-- This is f- uh, uh, this is wonderful, right?
- 29:18And what I'm learning here, though, is, is, is, is that there seems to be a virtuous loop.
- 29:24What you're talking about in terms of data is creating a virtuous loop between the trials that you're undergoing and the reduction of administrative bog and actual healing at the bedside.
- 29:39That essentially all of these are connected.
- 29:42This is a, this is sort of this and this, and the-- And, and what I mean by a virtuous loop is that as data becomes more readily available for, for you and other pr- uh, practitioners to use, that helps automate and speed up, um speed up the reimbursement process.
- 30:03It, it d-, it drives more accuracy around reimbursement and, um, the analysis therein.
- 30:09It also helps, um, clinicians at the bedside provide, provide better healing results through diagnostic equipment, through, through, through better intelligence that, that helps people, and that's ultimately the end of it.
- 30:23That's the goal of it, right?
- 30:24Um, is that- Love that … do I have that right?
- 30:26No, it's good.
- 30:27I mean, it's good.
- 30:27And, and that's, uh, I mean, it's funny because that's always the way it's been in medicine, but now it's really kind of come to the forefront in, in the wound care specialty itself, where we really, you know, uh, where, where you really do see that clinic- what the data from clinical trials feeds into the clinic itself, uh, and then feeds back again.
- 30:43You know, so, uh, it, it's, it's a quality loop.
- 30:47That strips out human measurement completely- Yeah … in that, in that, that example, right?
- 30:53And, and wound care being the most precise and complex of care, in my opinion- Mm-hmm… um, is now m- more reliant on of precision in that data in order to move forward across diagnostic and reimbursement, uh, frontiers.
- 31:14Is that right?
- 31:15Uh, yeah, yeah, I agree with that.
- 31:16I agree with that 100%.
- 31:18You know, so one of the, one of the most striking things that we found in clinical trials was that, uh, for example, your ability to detect clinical s- uh, bacterial burden within a wound based on clinical signs and symptoms, the accuracy of your eye is about 15%, and in dark-skinned individuals, it's 3%.
- 31:37So you just can't do it.
- 31:39I mean, you- we've got all those check click boxes for, you know, for, uh, for that, you know.
- 31:43But I would've, in a million years, I would never have guessed that that clinical examination was that poor, uh, uh, as far as sensitivity is concerned.
- 31:53Uh, and, uh, uh, so, a- and that's a real… And that was a major change in, in wound care.
- 31:59And although you still see people, you know, pop- you know, they got their little charts out and they're talking about Yeah.
- 32:04Well, the patient had, you know, a little bit of a hypergranulation tissue and it had a little extra drainage and, uh, we think therefore there's biofilm there.
- 32:12I mean, still peop- that publication is still coming out today, still hear it at meetings.
- 32:16That is all crap.
- 32:18Sorry to use the language, but it is.
- 32:20W- we were able to show that none of those symptoms cor- we did a ROC, uh, uh, you know, did a ROC curve and none of those symptoms at all correlate with bacterial burden.
- 32:31It's not, it's completely random.
- 32:33And, uh, and yet you still, you, you still… So that's one of the great things about research, very humbling.
- 32:37I have to go back and delete all of my YouTubes from like 10 years ago because they're all wrong.
- 32:42So- So where, where does that leave the clinician though, as far as, you know, the, the level of precision is beyond what a human can provide, right?
- 32:50That's what you're saying.
- 32:51That's what I hear you saying.
- 32:52Yeah.
- 32:52The, the, the, the, that level now creates a, creates a scenario in which what we thought was the, the healing path is not the healing path or is related and there's a better way, right?
- 33:08Um, where does that put the clinician in the loop?
- 33:11It's a tough spot, right?
- 33:12Because you've got, you've got monetary constraints.
- 33:15You know, wound care is probably one of the, it has one of the biggest monetary constraints of any other, uh, any of the specialties.
- 33:21And, uh, so you, you know, can you incorporate this technology, which isn't terribly expensive in the grand scheme of capital equipment in hospitals.
- 33:29Uh, so, uh, you've, you've gotta… If you can't incorporate this technology, then you're stuck, you know, in, you know, i- in, uh, you know, very, you know, Jurassic wound care.
- 33:39Uh, and, uh, and that's what you're practicing, and you're stuck practicing there.
- 33:44You know, I was excited about diagnostics because it really moved us out, out of that, you know?
- 33:48Uh, and there's more diagnostics to coming down the road.
- 33:51I mean, it's not just the ones that we mentioned.
- 33:53There's, there's, um, there are some, there, there's more coming out, uh, and, uh, o- we need them all.
- 34:00We need it 'cause, uh, your, your clinical examination i- is limited.
- 34:05It's not… Y- I'm not saying don't stop.
- 34:07I'm not saying don't fill out your documentation on clinical examination.
- 34:11You better fill it out.
- 34:12And it's still very important, but you need to add on.
- 34:16You mentioned this on another, on another podcast, and so I want… Can, what does that mean, Jura- Jurassic care?
- 34:21What do you mean by that?
- 34:23So, yeah, so, uh, now you're learning what I did in undergrad.
- 34:26So my undergraduate, uh, research was in evolutionary biology, so, um, so I have this sort of, um, um, evolutionary bent in my, in my brain, if you will, a defect.
- 34:38Anyway, the, um, uh, you know, so Jurassic care r- really means that you're, you are practicing medicine that is, that is, is antiquated, right?
- 34:48It's, it's, it's old.
- 34:50Uh, and, um, and you're gonna get Jurassic results if you perha- you know, if you perha- you know.
- 34:56Maybe you'll get Triassic results if you're really good.
- 34:59But, um, uh, but you're, uh, you're not g- you, you, you're not moving, you're not moving into the 21st century.
- 35:07Uh, and so, you know, we need to move- If you don't move, you're gonna be extinct, basically.
- 35:10Yeah, you're gonna be extinct.
- 35:11Yeah.
- 35:12Yeah.
- 35:12You, you know, um, that's, uh, um… Yeah.
- 35:15Yeah.
- 35:15Now, so we also- Where are we at now?
- 35:17Yeah.
- 35:17Where, where are we at now?
- 35:17Well, you know, I think we're, you know, I, I, you know, I'm, I'm, uh, I'm hopefully we're, hopefully we're in the modern era, but we'll see.
- 35:24I don't know.
- 35:25I think that, you know, the goal, my goal as a physician has always been to advance it as best as I can, as best I can, right?
- 35:30I wanna get, I wanna get to, you know, use the, um, the, all this technology to, uh, leverage all the technology to get us to the, uh, to get us to the best healing outcomes.
- 35:41That's really what we want.
- 35:43Yeah.
- 35:43Ultimately, you know, in, in, in all the research I did for, for this, for this interview, it came down to, it came back to your why being about healing ultimately.
- 35:55And like, and when I read that article and when I looked at, when I listened to the, um, um, some of the podcasts that you-- the most recent podcast that you've been, been a guest on, you, you always bring sort of solutions back to the healing moment, back to healing.
- 36:10That ultimately outcomes are the, the most important thing, almost to the point where that solves a lot of the challenges that wound care has today.
- 36:19Is that right?
- 36:20Yeah.
- 36:20It is.
- 36:21But, you know, I don't wanna go, you know… So I lo- I love healing as an outcome, you know, as a, it's, it's our most common endpoint.
- 36:26It's what really our, our goal is.
- 36:27And when you ask patients, when you do surveys, when you ask patients, "What do you want? What's the number one-- What do you want from this e- encounter with me?" The number one thing they answer is they want my wound to heal.
- 36:38That's number one.
- 36:39That's the most… A- and I think that's important.
- 36:41But they also, you know, like odor's another one, and we're doing a lot of research now on, on, um, smell and odor, um, because sometimes patients say, "What I really want is, is first, you know, I need this wound to stop smelling." And, uh, you know, and that's a really-- Uh, that sounds simple, but it is not easy.
- 36:58Uh, you know, i- if someone's draining like crazy and there's fluid everywhere and it smells, it's, it is, that's, that is a challenge.
- 37:06Um, and you know, one of the research we're doing now, uh, we can look for this in the future is, um, you know, is electronic noses.
- 37:13You know, something that will objectively smell the wound.
- 37:16It doesn't smell the wound, it just measures, you know, VOCs.
- 37:19But, uh, it gives you an idea of what the wound smells like, and that allows you… Once you have a tool, another diagnostic tool, but once you have a tool that tells you, uh, uh, what the level is, then you can begin to study and intervene and see if you can knock that level down.
- 37:35Uh, and, and, and the result is the patient has a, you know, the patient has a, a positive outcome, reduction in odor in my wound.
- 37:42I can go to church now and I'm not worried about it.
- 37:44So, so let me, let's pause there for a minute because, so the FDA is essentially, what, back in twen- 2006 said, uh, 100% complete wound closure, right?
- 37:53Right.
- 37:54Yeah.
- 37:54That's, that's the, um, the North Star that they sort of didn't mandate, but then kind of did, but, but basically mandated, right?
- 38:00Yeah.
- 38:00So, so that being the case, how-- What you're talking about is, tells me that tech, tech, AI, um, advanced technology is enabling a different sort of definition or a different sort of rule that makes that maybe not so much of a, um, of a North Star after all.
- 38:21Is that right?
- 38:22Yeah.
- 38:22I mean, s- complete healing's still gonna be the number one, your number one goal, but there are other outcomes that are important, as I mentioned, smell.
- 38:29Do, do I accelerate wound healing?
- 38:31Can I debride the wound?
- 38:32Those are important outcomes, and they need to be, you know… And FDA, I, I will tell you, has been more receptive.
- 38:37Uh, I'll g- I'll credit the wound care collaborative community for that.
- 38:40Um, uh, they've been more receptive to these alternative, uh, endpoints for their trial.
- 38:45And CMS, uh, still wants healing.
- 38:48They like healing a lot.
- 38:50But they are very in tune to, you know, patient-reported outcomes as well, so like odor.
- 38:55And, you know, I, I once had a conversation with one of the, uh, senior Medicare officials.
- 39:00It was a few years back.
- 39:02And, uh, a- and he said to me, "You know, Tom, if you could, if you could develop a product that reduces odor, uh, that we would pay for that because that's important to our, to our beneficiaries." So whether or not they actually pay for it or not, that's a different story, but I, I, I did believe him.
- 39:20I, and I… So I, I think that there is a role outside of complete wound healing, um, uh, for other end, other endpoints.
- 39:28There is-- There, they're gonna be a struggle, though.
- 39:30Right now it's, after all these years, uh, it's still difficult to get four week, you know, 40% at four weeks to be, to be, uh, get FDA to approve that or Medicare to accept it.
- 39:40The simple fact that if somebody can notice a difference and, uh, notice a difference in the odor, that, that encourages them to continue on their pr- on their program and continue on their, on their path is huge in and of itself.
- 39:54Yeah.
- 39:55Because they feel the, the patient would feel so much more encouraged as a result, right?
- 39:59Yeah.
- 40:00And that's- Yeah… that's, that's technology Yeah.
- 40:03Which is, which is crazy.
- 40:04Um, okay.
- 40:06You- We're about out of time, but I wanna, I wanna ask you a couple more questions- Sure … about, um, about how, how you're using technology in your, in your, in your clinical trials, and sort of how that has helped be more accurate and be faster, right?
- 40:23Is there a direct correlation between what that nurse is doing at the bedside, taking a picture of a wound, and your clinical registries and, and what you're doing in, in clinical trials?
- 40:35And how does that, how does that process work?
- 40:39So, I mean, AI's made a gigantic difference on the clinical trial side, right?
- 40:43You know, we have a lot less regulations than, say, we would in the clinic, uh, if we're using Wound Expert, whatever.
- 40:48If we're in a clinic using, uh, our regular EMR, we've gotta follow the electronic health act, blah, blah, blah, blah, blah.
- 40:53You know that better than I do.
- 40:55Uh, but in the clinical trials, uh, you know, especially the, the, the physician-initiated ones, um, we, we can plop AI right into the API for, um, our simple electronic data capture system, which is really a, a very simple system.
- 41:09It just… It's not a, it's not really an, it's not an EMR, right?
- 41:12It's just a simple data collection system.
- 41:14But we can put AI right in it, and, uh, and AI can monitor what the nurse at the bedside's doing, make sure that all the boxes are filled in.
- 41:22But more importantly, what, what, what the big holdup in clinical trials has always been is this big, long time it takes to lock the data.
- 41:31Three, four, five, six months to get the, before I get the data, uh, that I really want.
- 41:35And, you know, you can take six months and make it six, you know, six hours in, i- and also, um, uh, not to get too in the weeds here, but um Uh, the computing power now has allowed us to embrace, to embrace something called Bayesian statistics.
- 41:52And, um, Bayesian statistics is really interesting because it is actually, in my opinion, better than those standard frequentist P-value statistics, and FDA agrees with me.
- 42:03And the reason is, is because Bayesian assumes that you know something about the product.
- 42:08For so for skin subs, we know that we have data in the past that shows they're safe and effective.
- 42:13So in a Bayesian, um, example, we can put-- we can use that in our, in our current trial be- because we have prior knowledge.
- 42:22So, uh, and, and that has, that has revolutionized, and that's all basic, you know, AI and computing power that, uh, that enables us to, uh, to, uh, to, to utilize that.
- 42:34And, and, uh, what a year this has been, completely revolutionized, um, um… And, uh, we-- the Bayesian allowed us to build something called indi- uh, uh, individual patient data.
- 42:46I had never heard of IPD before this year.
- 42:48So I thought it was a disease of some kind.
- 42:50But anyway, IPD, individual patient data, FDA says that is the gold standard in control groups.
- 42:55Well, now that we have all these clinical trials running and we're able to get all that data and put it together, uh, we basically have a s- a standard of care healing rate that we know, and we know what that rate is, and we can use that in future clinical trials and say, "Okay, you don't need to enroll, you know, uh, you know, 100 standard care patients.
- 43:16You can enroll 10." And, uh, we'll then we'll pull from this IPD, and we can do a much smaller, much faster trial, and we don't have to give patients standard of care.
- 43:25I'm a provider.
- 43:26Let's say I'm a, let's say I'm a CTO.
- 43:28I'm gonna, I'm gonna give myself a raise.
- 43:30I'm gonna be a CTO, right?
- 43:33And, and, and I'm listening to you, and I'm thinking to myself, "Okay, you're, you're playing with the FDA.
- 43:39You're, you're playing with CMS.
- 43:41You're, you're the expert in the room when it comes to those two agencies." Um, where are they at in terms of their evolution toward technology, toward AI?
- 43:52And what do I, as a provider, need to be prepared for and need to, need to do in order to ensure accurate payment and, and better outcomes?
- 44:06So let's talk FDA first.
- 44:07You know that if you send a submission to the FDA, they're gonna run it through AI.
- 44:11They've already told everybody.
- 44:12It's called Alyssa, I think is the name of it, they use.
- 44:14So they use a program, they take your submission and run it through AI.
- 44:18So if you're not running your submission through AI before you send it to them You're in trouble.
- 44:23Uh, you know, so we actually have built a, uh, they won't list… It, it's really a black box where the FDA is.
- 44:30We have no idea.
- 44:31There's n- we, we've looked everywhere online.
- 44:34We can't find any information on this at all.
- 44:36We know it was probably started in Claude.
- 44:38That's all we know.
- 44:39But so we kind of looked at it and we said, "Okay, we'll build our own AI that looks like the FDA AI, and then we'll train it.
- 44:46We'll, we'll put trials in it and see what it says, and then we'll compare it to what FDA says." So, uh, so on the FDA side, you've gotta have AI.
- 44:53You have no choice.
- 44:55And it's, that's happening on the CMS side.
- 44:57Wisr, we mentioned earlier.
- 44:58Uh, you know, if, you know, i- if, if Medicare's gonna run your, your charts through AI, you better run it through AI first, you know, so it can pick up, "Oh, hey, d- you didn't, you didn't check that nutrition box.
- 45:12Um, you, I know you probably did it, but you didn't check that box.
- 45:14Go back and check that box." So, um, uh, you know, I, I think that, um, uh, y- the, it's not an option.
- 45:22Do I, do I play with AI or not play with AI?
- 45:25That's not, that, that ship has sailed.
- 45:27You either, you either gonna play with AI or you'll stay in the Jurassic period and go extinct because, uh, your, your regulatory agencies are using it to oversee you.
- 45:39So you ha- you've gotta use it too.
- 45:42And how do you keep your clinicians in the loop and not burning out or despondent over the fact that AI is now providing more pr- more precise, um, measurements and more profice- precise analysis of the wou- the wound care that they were originally providing in the first place?
- 45:59I, I think the providers find it, you know, providers love it, right?
- 46:03They love it because why?
- 46:05Because it takes less paperwork time.
- 46:06You know, uh, there was that report that came out in like 2022 or something that said that, uh, that they estimated that the providers spend 51% of their time charting We, you know how much time we really wanna spend charting?
- 46:16Zero.
- 46:17We wanna s- we, we went into this to spend time with our patients, and that's what we wanna do.
- 46:21I, I get, I get no pushback from providers and nurses at all.
- 46:25They love AI.
- 46:26Um, well, we all don't really trust it all that much, but we love it.
- 46:29And, um, and, you know, and it'll get better.
- 46:32Uh, it'll get better over time.
- 46:34Uh, but I don't see it… I, I, most clinicians kind of laugh when they say, "Oh, it's gonna re- you know, it's gonna replace," you know, like a wound physician.
- 46:42Oh, come on.
- 46:43You know, AI's not gonna be able to wield a scalpel.
- 46:45And honestly, what AI's really good at is diagnosis.
- 46:49You know what?
- 46:50I'm right about 99.9% of the time on diagnosis.
- 46:53Don't really need that help.
- 46:55What I need help with is sure up my documentation to make sure I put everything in that piece, uh, in my EDC.
- 47:02Make sure that my electronic data capture, or that my EMR is compliant so that when Medicare uses their AI, I pass.
- 47:10That's what I really need A- AI for, and that's where it really works really well, and to decrease my, my, my chart burden so that it can record, it can record data much like a scribe would.
- 47:21I mean, it's basically you took the kids that were scribes and just made them AI now.
- 47:25Uh, and, uh, and that's really, that decreases burnout, that increases professional satisfica- satisfaction, and improves, improves outcomes.
- 47:33There's so many studies out there right now that so show that what AI is doing is essentially taking the common, common treatment, the common diagnosis away from, from human input- Yeah and leaving, leaving human involvement, the human in the loop, to those more complex, more problematic diagnosis and, and healing journeys that they're, that, that are- Yeah … that are required to have somebody who is actually deeply involved.
- 48:03That's- Right.
- 48:04Right.
- 48:04That's- Yeah, I mean, I, I can't think of the last time I used AI to help me with a diagnosis Or need to.
- 48:10Uh, but, you know, but can you pull the fi- last five papers on that diagnosis?
- 48:14Well, there it is right there.
- 48:16It's beautiful.
- 48:16You know, and normally that would've required a, you know, in the Jurassic era, I'd had to go to the library and look all that stuff up.
- 48:22Uh, you know, so, uh, it just, it- that's an enormous time saver.
- 48:26A- and it's, it's, it's time that's not very well spent, right?
- 48:32Why not have AI do it?
- 48:33I mean, it, you, you… I wanna spend my time talking to the patient, you know, getting the da- you know, getting input, uh, from the patient, you know,'cause it's, you know, the other thing about it, all, all EMRs, all data capture systems, if, if you, if you feed it garbage, it gives you garbage.
- 48:47You've gotta get, you've gotta get good data into the system.
- 48:51That's one thing that we've learned a lot in the last two years.
- 48:53Um, boy, you, you, you, at, at, at the, at the interface between the patient and the nurse and doctor, uh, that data collection has to really be good, solid, right?
- 49:04Because if it's not, you can put, you can put, you know, a million dollars worth of AI in there, it wouldn't make a damn's worth bit, uh, difference.
- 49:11You need good data.
- 49:12You need a good database in order to build, uh, uh, in order to make AI really work well.
- 49:19So, so just a couple more questions.
- 49:21Uh, th- this, this, this one is about your background a little bit.
- 49:25I noticed in, and I noticed in, in, in reading about what you've done, that you have taken a very global view of, of wound care, um, in, in your, in your research.
- 49:37From the US, South Africa, Greece, Cyprus, you have-- You, you're always on a plane.
- 49:42You're always- … you're always going somewhere.
- 49:45And, and, and it's, and, and it's, it's sort of been, I think, and, and tell me if this is, if this is wrong, but it really feels like a foundational part of what you've built with Serena Group.
- 49:55Talk to me about how that's made a difference in terms of what you're providing, um, what, what you provide with the group.
- 50:03Well, one of the things I've always thought about wound care, what I've always loved about wound care is it's universal.
- 50:07It's a problem no matter where you go.
- 50:08You can't fly on a plane anywhere and, you know, throw a dart at, on a globe somewhere, and they've got a wound care problem.
- 50:14And, you know, it just became part of what we wanted to do, is expand beyond, uh, the borders.
- 50:19Also, when you're doing clinical research, um, you know, certain countries, uh, uh, do great job at, at collecting data and, uh, um, and, and are just a great resource, like South Africa.
- 50:30Fabulous wound clinics.
- 50:31They're terrific, uh, practitioners.
- 50:33Um, great place to do, uh, great place to gather, uh, data, and expands what we have, uh, uh, in the, in, in the US.
- 50:41Um, and, you know, Cyprus and Greece, uh, similarly, uh, you know, it's m- very American-like population.
- 50:48Easy, um, e- uh, nice and easy to study, nice places to visit.
- 50:51So, um, uh, it's, it's just another way to gather, uh, to gather, uh, data to keep the diversity of your data solid.
- 51:00So your data's not all coming from one center, you know, in Pittsburgh or something, you know?
- 51:03So it's, you know, you, it's, y- you've got a diversity of data, and you'll… A- and not just a- any, as our statisticians will tell you, the more diverse the data collection is, the better your data is.
- 51:14What keeps you getting on the plane?
- 51:15I mean, what, what, what keeps you in the Delta Sky Lounge for f- you know, week after week?
- 51:20What's driving you?
- 51:21Um, you know, I, I love what I do.
- 51:23I mean, I, I got the greatest job in the world, right?
- 51:25So, um, I mean, we get, uh, people present us with problems and, and we have to solve those problems.
- 51:31And, uh, they, they come up with ideas, and we've gotta show that the ideas work, or don't work for that matter, which is the harder part.
- 51:37And so, uh, you know, it, it, it's really an exciting life.
- 51:40People say to me, "When are you gonna retire?" I said I don't know.
- 51:44Not, not… No plans.
- 51:45No plans at all to retire.
- 51:46I'm having way too much fun.
- 51:47Uh, this is just a great, th- this is just a great, it's been a great opportunity for me.
- 51:51I could not, like I said, uh, I'm blessed.
- 51:53There's no doubt about it.
- 51:54And I've got a, I got a great team.
- 51:56I mean, I, you know, I, I take a lot of credit for it, uh, but I have a fabulous team.
- 52:01I mean, our team is unmatched in its, um… A- and we're all, we all think the same way, really.
- 52:06I mean, everybody's thinking, "Now, how am I gonna get that wound healed?
- 52:09How am I gonna decrease that odor?
- 52:10How am I gonna, you know, how are we gonna detect this?" Or what, you know, what, you know, how are we gonna keep pa- patients from getting standard care anymore?
- 52:18We, we don't want them to get that.
- 52:20So it's… And everybody's on the same page.
- 52:22Everybody is focused on, uh, uh, uh, on this, and it's very exciting.
- 52:27What do you think that, what, what does the future hold?
- 52:29Like five years from now, what are you gonna, what are you gonna be talking about?
- 52:32What, what podcast… You're gonna be on a podcast somewhere.
- 52:35What are you gonna be talking about five years from now?
- 52:37What does that picture look like?
- 52:38I don't know what I'm gonna be talking about five months from now.
- 52:40So, so, um, well, I, I hope in five years that we're talk, you know, that, that we are, uh, that we're talking about, uh, you know, the importance of data and, and, and I think we will be.
- 52:54You know, we'll be using data, data-driven decisions.
- 52:57You know, uh, you know, uh, Christina Harrell and I, uh, are doing the pressure, a lot of the pressure ulcer research right now.
- 53:04And pressure ulcer care is completely driven by people's opinions.
- 53:09And I know from my own opinions that they are, yeah, they may not be right.
- 53:14Uh, and that is, I can't tell you how exciting that is, um, that we're beginning to get data on, on, uh, on, um, on pressure, on, on pressure ulcers or injuries, whatever you wanna call them.
- 53:27But it may be that they're not pressure related at all.
- 53:29There may be a whole subset, I know there is, a whole subset of ulcers that are vascular, that what's happening in, with that sacral ulcer in the ICU is it's an infarction.
- 53:41It has nothing to do with pressure at all.
- 53:43Zero.
- 53:43It's not pressure ulcer.
- 53:44I, I literally just heard the subject matter experts on the wound care side of our business, their, their brains explode.
- 53:50That's- Oh, right.
- 53:53So, you know, and we've been, we've been doing some work, uh, and I gotta just give a shout-out to the San Antonio Cadaver Lab, who has allowed me to come in and do cad- cadaveric studies and anatomic studies.
- 54:03Um, and it is really clear that, um, uh, that, uh, that y- particularly in ICU, particularly in your spinal cord injured population, that it has nothing to do with pressure.
- 54:13These are vascular ulcers.
- 54:14They're, they're heart attacks in your sacrum.
- 54:16And, um, uh, and, uh, that has a lot of implications, uh, on the medical legal side of, of, of the business, which is real exciting.
- 54:24So I'll give a shameless plug.
- 54:25We have a pressure ulcer summit coming up in February 5th and 6th.
- 54:28We're gonna talk about it there.
- 54:30And not only that, we'll talk about this infarction idea, and we've got a pathologist who's done all these biopsies on… And we'll have histopathology, we'll have, uh, you know, cadaveric anatomy and, and, uh, angiosome data from that.
- 54:42Uh, like I said, why would I retire, man?
- 54:44This is way too much fun.
- 54:45So Tom, thank you so much for walking us through your work and your, and your vision for the future.
- 54:51Uh, this is a critical moment in wound care, man, and, and I feel like as though the importance that technology is bringing to it is, is helping find solutions as well as opening up new doors.
- 55:01So thank you very much for taking the time.
- 55:03I, I really appreciate, uh, your time.
- 55:04My pleasure.
- 55:05And I-- And to the audience too, if you haven't embraced AI, you wanna email me.
- 55:09I have a whole AI department, but you know, if you haven't embraced AI, now's the time.
- 55:12It's not really too late yet, but, uh, it will be.
- 55:15It will be.
- 55:15You'll be either in the cr- you'll be either in with AI or out or outside.
- 55:19You just-- Whether you like it or not, doesn't matter.
- 55:21You gotta have it.
- 55:27All right, recap time.
- 55:28Here are the top three things I took away from my conversation with Dr. Serena today.
- 55:33First, when policy goes old school, technology must become your defensive shield.
- 55:40To survive in this flat rate era without bleeding margins or drowning in audits, providers must use point-of-care AI to build indisputable algorithmic proof documentation before a claim ever leaves the clinic.
- 55:54Second, technology must actively reduce the friction of care, not add to it.
- 56:00We cannot solve a massive public health epidemic if our frontline clinicians are drowning in administrative burdens and regulatory paperwork.
- 56:09True health tech innovation should streamline workflows rather than increase the cognitive load, allowing bedside providers to focus
- 56:18on what matters most: the patient.
- 56:20on what matters most: Finally, clean data at the bedside unlocks a global fast track for medical innovation.
- 56:26on what matters most: When we use advanced tech like tissue analytics or Moleculight, we aren't just protecting a clinic's revenue, we are feeding clinical registries.
- 56:36on what matters most: This enables breakthrough methodologies like virtual control arms that bypass recruitment bottlenecks, helping us bring life-saving biological therapies to suffering patients years ahead of schedule.
- 56:48on what matters most: And that's it for another episode of Humanify Health Tech.
- 56:51on what matters most: As always, thank you for tuning in.
- 56:53on what matters most: If you're joining us on Spotify or YouTube, we'd love to hear your thoughts in the comments below.
- 56:59on what matters most: Don't forget to leave us a rating and subscribe while you're there to stay up to date on how trusted infrastructure is changing clinical AI.
- 57:08on what matters most: Once again, I'm Brian Chi from Net Health, and I'll see you next time